High genomic grade index associated with poor prognosis for lymph node-negative and estrogen receptor-positive breast cancers and with good response to chemotherapy

Cancer

Volumn 117, Issue 3, 2011, Pages 472-479

  Naoi, Yasuto ^a   Kishi, Kazuki ^b   Tanei, Tomonori ^a   Tsunashima, Ryo ^a   Tominaga, Naoomi ^a   Baba, Yosuke ^b   Kim, Seung Jin ^a   Taguchi, Tetsuya ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SYSMEX CORPORATION   (Japan)

Author keywords

breast cancer; chemotherapy; DNA microarray; genomic grade index; prognosis

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TOREMIFENE;

ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DNA MICROARRAY; FEMALE; GENE EXPRESSION PROFILING; GENOMIC GRADE INDEX; HUMAN; HUMAN TISSUE; JAPANESE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; ONCOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROGNOSIS; TUMOR VOLUME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; GENES, ERBB-2; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; NEOPLASMS, HORMONE-DEPENDENT; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTORS, ESTROGEN; TREATMENT OUTCOME;

EID: 79251480077     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25626     Document Type: Article

References (11)

1. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006; 98: 262-272.
2. Desmedt C, Giobbie-Hurder A, Neven P, et al. The gene expression grade index: a potential predictor of relapse for endocrine-treated breast cancer patients in the BIG 1-98 trial. BMC Med Genomics. 2009; 2: 40.
3. Loi S, Haibe-Kains B, Desmedt C, et al. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 2007; 25: 1239-1246.
4. Liedtke C, Hatzis C, Symmans WF, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol. 2009; 27: 3185-3191.
5. Morimoto K, Kim SJ, Tanei T, et al. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci. 2009; 100: 1062-1068.
6. Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009; 15: 4234-4241.
7. Elston CW, Ellis IO., Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19: 403-410.
8. Haibe-Kains B, Desmedt C, Piette F, et al. Comparison of prognostic gene expression signatures for breast cancer. BMC Genomics. 2008; 9: 394.
9. Viale A, Li J, Tiesman J, et al. Big results from small samples: evaluation of amplification protocols for gene expression profiling. J Biomol Tech. 2007; 18: 150-161.
10. Clement-Ziza M, Gentien D, Lyonnet S, Thiery JP, Besmond C, Decraene C., Evaluation of methods for amplification of picogram amounts of total RNA for whole genome expression profiling. BMC Genomics. 2009; 10: 246.
11. Toussaint J, Sieuwerts AM, Haibe-Kains B, et al. Improvement of the clinical applicability of the genomic grade index through a qRT-PCR test performed on frozen and formalin-fixed paraffin-embedded tissues. BMC Genomics. 2009; 10: 424.